tiprankstipranks
Trending News
More News >
AbbVie (ABBV)
NYSE:ABBV
US Market

AbbVie (ABBV) Stock Forecast & Price Target

Compare
22,604 Followers
See the Price Targets and Ratings of:

ABBV Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
13 Buy
6 Hold
0 Sell
Based on 19 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$212.13
▲(13.23%Upside)
Based on 19 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $212.13 with a high forecast of $250.00 and a low forecast of $170.00. The average price target represents a 13.23% change from the last price of $187.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"154":"$154","251":"$251","178.25":"$178.3","202.5":"$202.5","226.75":"$226.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$250.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":212.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$212.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$170.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[154,178.25,202.5,226.75,251],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,191.83692307692309,196.68384615384616,201.53076923076924,206.3776923076923,211.2246153846154,216.07153846153847,220.91846153846154,225.76538461538462,230.6123076923077,235.45923076923077,240.30615384615385,245.15307692307692,{"y":250,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,188.92384615384617,190.8576923076923,192.79153846153847,194.72538461538463,196.65923076923076,198.59307692307692,200.52692307692308,202.46076923076924,204.39461538461538,206.32846153846154,208.2623076923077,210.19615384615383,{"y":212.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,185.68307692307692,184.37615384615384,183.06923076923078,181.7623076923077,180.45538461538462,179.14846153846153,177.84153846153848,176.5346153846154,175.2276923076923,173.92076923076922,172.61384615384617,171.30692307692308,{"y":170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":155.59,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.74,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.99,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$250.00Average Price Target$212.13Lowest Price Target$170.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ABBV
TipRanks AITipRanks
Not Ranked
TipRanks
$201
Hold
7.29%
Upside
Reiterated
05/31/25
AbbVie's stock score is driven primarily by strong earnings call highlights and solid financial performance, despite high leverage and valuation concerns. The company's strategic investments and guidance adjustments indicate positive long-term growth prospects. However, potential financial risks due to leverage and high P/E ratio warrant cautious optimism.
Morgan Stanley Analyst forecast on ABBV
Terence FlynnMorgan Stanley
Morgan Stanley
$250
Buy
33.45%
Upside
Reiterated
06/03/25
AbbVie's Promising Growth Trajectory: Strong Pipeline, Strategic Investments, and Global Expansion
Bernstein
Hold
Reiterated
05/31/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD)
Berenberg Bank Analyst forecast on ABBV
Luisa HectorBerenberg Bank
Berenberg Bank
$195$170
Hold
-9.26%
Downside
Reiterated
05/30/25
Berenberg Bank Sticks to Its Hold Rating for AbbVie (ABBV)
Bank of America Securities Analyst forecast on ABBV
Tim AndersonBank of America Securities
Bank of America Securities
$204
Hold
8.89%
Upside
Reiterated
05/15/25
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)
Citi
$210$205
Hold
9.43%
Upside
Downgraded
05/15/25
AbbVie downgraded to Neutral from Buy at CitiAbbVie downgraded to Neutral from Buy at Citi
DBS
$183
Hold
-2.32%
Downside
Reiterated
05/14/25
AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties
Guggenheim Analyst forecast on ABBV
Vamil DivanGuggenheim
Guggenheim
$214$216
Buy
15.30%
Upside
Reiterated
04/29/25
AbbVie price target raised to $216 from $214 at GuggenheimAbbVie price target raised to $216 from $214 at Guggenheim
Leerink Partners Analyst forecast on ABBV
David RisingerLeerink Partners
Leerink Partners
$210
Buy
12.10%
Upside
Reiterated
04/28/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD), AbbVie (NYSE: ABBV) and Molecular Partners (NASDAQ: MOLN)
HSBC
$230$205
Buy
9.43%
Upside
Reiterated
04/28/25
AbbVie price target lowered to $205 from $230 at HSBCAbbVie price target lowered to $205 from $230 at HSBC
BMO Capital Analyst forecast on ABBV
Evan SeigermanBMO Capital
BMO Capital
$215
Buy
14.76%
Upside
Reiterated
04/28/25
BMO Capital reiterates Outperform Rating on Abbvie (ABBV)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $215.00 price target on Abbvie (NYSE: ABBV)
Raymond James Analyst forecast on ABBV
Gary NachmanRaymond James
Raymond James
$220$227
Buy
21.17%
Upside
Reiterated
04/28/25
AbbVie price target raised to $227 from $220 at Raymond JamesAbbVie price target raised to $227 from $220 at Raymond James
TD Cowen Analyst forecast on ABBV
Steve ScalaTD Cowen
TD Cowen
$250
Buy
33.45%
Upside
Reiterated
04/25/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on ABBV
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
04/25/25
AbbVie's Strong Financial Performance and Growth Potential Justifies Buy Rating
Cantor Fitzgerald Analyst forecast on ABBV
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$210
Buy
12.10%
Upside
Initiated
04/22/25
AbbVie initiated with an Overweight at Cantor FitzgeraldAbbVie initiated with an Overweight at Cantor Fitzgerald
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ABBV
TipRanks AITipRanks
Not Ranked
TipRanks
$201
Hold
7.29%
Upside
Reiterated
05/31/25
AbbVie's stock score is driven primarily by strong earnings call highlights and solid financial performance, despite high leverage and valuation concerns. The company's strategic investments and guidance adjustments indicate positive long-term growth prospects. However, potential financial risks due to leverage and high P/E ratio warrant cautious optimism.
Morgan Stanley Analyst forecast on ABBV
Terence FlynnMorgan Stanley
Morgan Stanley
$250
Buy
33.45%
Upside
Reiterated
06/03/25
AbbVie's Promising Growth Trajectory: Strong Pipeline, Strategic Investments, and Global Expansion
Bernstein
Hold
Reiterated
05/31/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD)
Berenberg Bank Analyst forecast on ABBV
Luisa HectorBerenberg Bank
Berenberg Bank
$195$170
Hold
-9.26%
Downside
Reiterated
05/30/25
Berenberg Bank Sticks to Its Hold Rating for AbbVie (ABBV)
Bank of America Securities Analyst forecast on ABBV
Tim AndersonBank of America Securities
Bank of America Securities
$204
Hold
8.89%
Upside
Reiterated
05/15/25
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)
Citi
$210$205
Hold
9.43%
Upside
Downgraded
05/15/25
AbbVie downgraded to Neutral from Buy at CitiAbbVie downgraded to Neutral from Buy at Citi
DBS
$183
Hold
-2.32%
Downside
Reiterated
05/14/25
AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties
Guggenheim Analyst forecast on ABBV
Vamil DivanGuggenheim
Guggenheim
$214$216
Buy
15.30%
Upside
Reiterated
04/29/25
AbbVie price target raised to $216 from $214 at GuggenheimAbbVie price target raised to $216 from $214 at Guggenheim
Leerink Partners Analyst forecast on ABBV
David RisingerLeerink Partners
Leerink Partners
$210
Buy
12.10%
Upside
Reiterated
04/28/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD), AbbVie (NYSE: ABBV) and Molecular Partners (NASDAQ: MOLN)
HSBC
$230$205
Buy
9.43%
Upside
Reiterated
04/28/25
AbbVie price target lowered to $205 from $230 at HSBCAbbVie price target lowered to $205 from $230 at HSBC
BMO Capital Analyst forecast on ABBV
Evan SeigermanBMO Capital
BMO Capital
$215
Buy
14.76%
Upside
Reiterated
04/28/25
BMO Capital reiterates Outperform Rating on Abbvie (ABBV)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $215.00 price target on Abbvie (NYSE: ABBV)
Raymond James Analyst forecast on ABBV
Gary NachmanRaymond James
Raymond James
$220$227
Buy
21.17%
Upside
Reiterated
04/28/25
AbbVie price target raised to $227 from $220 at Raymond JamesAbbVie price target raised to $227 from $220 at Raymond James
TD Cowen Analyst forecast on ABBV
Steve ScalaTD Cowen
TD Cowen
$250
Buy
33.45%
Upside
Reiterated
04/25/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on ABBV
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
04/25/25
AbbVie's Strong Financial Performance and Growth Potential Justifies Buy Rating
Cantor Fitzgerald Analyst forecast on ABBV
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$210
Buy
12.10%
Upside
Initiated
04/22/25
AbbVie initiated with an Overweight at Cantor FitzgeraldAbbVie initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month
xxx
Success Rate
16/26 ratings generated profit
62%
Average Return
+3.13%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +3.13% per trade.
3 Months
xxx
Success Rate
18/24 ratings generated profit
75%
Average Return
+7.67%
assigned a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.67% per trade.
1 Year
Christopher RaymondPiper Sandler
Success Rate
37/41 ratings generated profit
90%
Average Return
+22.00%
assigned a buy rating 4 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 90.24% of your transactions generating a profit, with an average return of +22.00% per trade.
2 Years
xxx
Success Rate
39/41 ratings generated profit
95%
Average Return
+38.39%
assigned a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 95.12% of your transactions generating a profit, with an average return of +38.39% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
26
27
30
23
19
Hold
9
10
11
13
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
37
41
36
29
In the current month, ABBV has received 19 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 212.13.
Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.22 with a range of $3.06 to $3.29. The previous quarter’s EPS was $2.46. ABBV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.
Next quarter’s earnings estimate for ABBV is $3.22 with a range of $3.06 to $3.29. The previous quarter’s EPS was $2.46. ABBV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $14.95B with a range of $14.50B to $15.18B. The previous quarter’s sales results were $13.34B. ABBV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.
Next quarter’s sales forecast for ABBV is $14.95B with a range of $14.50B to $15.18B. The previous quarter’s sales results were $13.34B. ABBV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?
Based on analyst ratings, AbbVie’s 12-month average price target is 212.13.
    What is ABBV’s upside potential, based on the analysts’ average price target?
    AbbVie has 13.23% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABBV a Buy, Sell or Hold?
          AbbVie has a consensus rating of Moderate Buy which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.
            What is AbbVie’s price target?
            The average price target for AbbVie is 212.13. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $250.00 ,the lowest forecast is $170.00. The average price target represents 13.23% Increase from the current price of $187.34.
              What do analysts say about AbbVie?
              AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of ABBV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis